Arthneeti
Latest: Suraksha Diagnostic Ltd Q1 FY27 (Apr–Jun 2026) results →This page is Q4 FY25 (Jan–Mar 2025).All Q4 FY25 results →
SD

Suraksha Diagnostic Ltd

Q4 FY25Healthcare Services

Suraksha Diagnostic Q4 FY25 earnings call: Revenue & Margins

Q4 FY25 earnings call: what management said on revenue, margins and capex.

Price₹318
Market cap₹1.6K Cr
P/E44.4
Updated26 Aug 2026
Read4 min read

The short version

Expected revenue growth for FY '26 is around 18%-20% compared to FY '25. Expecting revenue growth of 18%-20% in FY '26 compared to FY '25. - Anticipated EBITDA margin around 36% for FY '26, up from 34% in FY '25. - Continued margin expansion despite new centers opening due to improved operating leverage and mature centers absorbing fixed costs. - Profit After Tax (PAT) showed strong 34% growth in FY '25; further growth expected with scaling operations. - Business model's strong B2C focus (>93% revenue) supports sustainable margins. - Ongoing addition of 15-18 centers planned in FY '26 to drive volume and profitability. - CAPEX planned at around Rs.

From Suraksha Diagnostic Ltd's Q4 FY25 earnings-call transcript · updated 26 Aug 2026.

Revenue & Sales Performance

  • Expected revenue growth for FY '26 is around 18%-20% compared to FY '25.
  • Volume of tests conducted has been growing at around 10% year-on-year between FY '24 and FY '25.
  • Price increases are planned at around 2%-3% every alternate year.
  • Market share impact from new competitors entering Eastern India has not been seen yet.
  • Opening 15-18 new centers in FY '26, including 8 centers in the first quarter itself, supports growth.
  • Expansion plans focused on Eastern India with potential acquisitions if suitable.

2 more points from Suraksha Diagnostic Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Suraksha Diagnostic Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Planned CAPEX for FY '26 is around Rs. 70 crore (Ritu Mittal).
  • CAPEX mainly for opening new centers: 4 big centers (~Rs. 10 Cr each) and 4 small centers (Rs. 1.5-2 Cr each).
  • Additional CAPEX may depend on PPP centers, but exact numbers unknown due to tender-based process.
  • Strategic investment includes establishment of MRI at Calcutta Medical College within 90 days.
  • Investment to build genomic lab, expected to launch soon, enhancing B2B business.
  • Focus on expanding the network with 15-18 new centers planned in FY '26.

2 more points from Suraksha Diagnostic Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

Guidance-ranked
1Health X Platform
Rev 1Mar 1
2Chandan Healthca
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 1
5
Rev 2Mar 2
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Suraksha Diagnostic Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • They are in the process of establishing an MRI center in Calcutta Medical College within the next 90 days, noted as a significant opportunity.
  • For the fiscal year 2026, Suraksha plans to add approximately 15-18 new centers.
  • In the first quarter of FY '26, they have already opened 5 centers and plan to open 3 more shortly, totaling 8 centers.

2 more points from Suraksha Diagnostic Ltd's call on order book

Create a free account to keep reading this call

Suraksha Diagnostic Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹81 Cr, net profit ₹6 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Suraksha Diagno.'s management said in earlier quarters

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Suraksha Diagnostic Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Suraksha Diagnostic Ltd Q4 FY25 results?

Expected revenue growth for FY '26 is around 18%-20% compared to FY '25. Expecting revenue growth of 18%-20% in FY '26 compared to FY '25. - Anticipated EBITDA margin around 36% for FY '26, up from 34% in FY '25. - Continued margin expansion despite new centers opening due to improved operating leverage and mature centers absorbing fixed costs. - Profit After Tax (PAT) showed strong 34% growth in FY '25; further growth expected with scaling operations. - Business model's strong B2C focus (>93% revenue) supports sustainable margins. - Ongoing addition of 15-18 centers planned in FY '26 to drive volume and profitability. - CAPEX planned at around Rs.

What is Suraksha Diagnostic Ltd share price analysis?

Suraksha Diagnostic Ltd currently shows a neutral. The stock trades at a P/E of 44.4 with a market cap of ₹1,588 Cr. Investors should review the full earnings analysis for detailed insights.

Is Suraksha Diagnostic Ltd planning capital expenditure?

Planned CAPEX for FY '26 is around Rs.

Keep Suraksha Diagnostic Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.